南方财经8月28日电，华强科技（688151.SH）近日发布2025年半年度报告。公司实现营业收入1.78亿 元，同比减少25.98%；归属于上市公司股东的净利润413.32万元，同比骤降84.49%；扣非后净利润 为-3351.14万元；经营活动产生的现金流量净额为-2343.87万元。 特种防护装备板块收入同比减少28.63%，毛利率表现尤为惨淡，从上年同期的23.76%暴跌至-3.47%。 主要因军品订单交付集中在四季度，上半年在手订单未达交付节点，产能利用率不足，导致板块陷入亏 损。医药包装及医疗器械板块主导产品药用丁基胶塞收入同比减少29.68%。 报告期内，公司对多项募投项目进行重大调整："新型核生化应急救援防护装备产业化生产基地项目"总 投资从7.72亿元调减至3.88亿元；"新型核生化防护基础材料研发平台建设项目"从3.53亿元调减至3.40亿 元。同时，这两个项目及"信息化（数据驱动的智能企业）建设项目"的预定可使用状态日期均延后至 2028年12月；原计划2025年完成定型的项目延期至2028年。新增的"新型给药装置及包装材料研发与产 业化项目"投资3.98亿元，建设周期36个月。 值得注 ...

湖北华强科技股份有限公司2025 年半年度报告 公司代码：688151 公司简称：华强科技 湖北华强科技股份有限公司 湖北华强科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中描述公司面临的风险，敬请查阅本报告"第三节 管理层讨论与分析"之 "四、风险因素"部分，请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人孙光幸、主管会计工作负责人孙岩及会计机构负责人（会计主管人员）章博声 明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 九、 是否存在被控股股东及其他关联方非经营性占用资金 ...

融资方面，华强科技当日融资买入2401.01万元。当前融资余额1.50亿元，占流通市值的1.71%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，华强科技8月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，湖北华强科技股份有限公司位于中国(湖北)自贸区宜昌片区生物产业园东临路499号，成立 日期2001年11月12日，上市日期2021年12月6日，公司主营业务涉及生产个体防护装备、集体防护装备, 以提升我国各军兵种在核生化威胁条件下的生存和作战能力;同时依托技术优势,积极开拓医药包装、医 疗器械等民品市场。主营业务收入构成为：药用丁基胶塞54.78%，集体防护装备26.37%，其他主营 9.97%，个体防护装备4.65%，其他(补充)4.22%。 8月25日，华强科技跌0.16%，成交额1.60亿元。两融数据显示，当日华强科技获融资买入额2401.01万 元，融资偿还2341.83万元，融资净买入59.18万元。截至8月25日，华强科技融资融券余额合计1.50亿 元。 分红 ...

Core Viewpoint - The financial performance of Huqiang Technology (688151.SH) reveals a facade of profitability, with a significant increase in net profit driven by non-recurring gains, while the core business continues to suffer losses [1][2]. Financial Performance - In 2024, the company's net profit attributable to shareholders surged by 184.26% to 22.53 million yuan, but the adjusted net profit showed a loss of 64.96 million yuan, marking four consecutive years of losses [1]. - The profit increase was largely due to investment income contributing 51.86 million yuan, accounting for 230% of the net profit, while the operating profit loss expanded to 78.36 million yuan [1]. Core Business Challenges - The core business faces structural crises, with military product revenue increasing by 68.31% to 161 million yuan, primarily reliant on a single product, the 239 model equipment, which generated 123 million yuan in revenue [2]. - Individual protective equipment revenue plummeted by 59.24% due to declining demand for key military products [2]. - The pharmaceutical packaging segment also experienced significant declines, with revenue dropping by 89.36% in Q1 2025 [3]. Investment Projects and Liquidity Issues - Investment projects from the IPO are nearly stagnant, with the highest progress at only 32.77% and the lowest at 0.48%, raising concerns about funding efficiency [4]. - The company has faced a three-year ban from participating in military procurement due to violations, leading to a sharp decline in new military orders [4]. - Cash flow issues are evident, with a 23.12% reduction in cash reserves compared to the previous year, indicating potential liquidity crises [4].

Core Viewpoint - The company reported a revenue of 611 million yuan for the year, a year-on-year increase of 6.74%, and a net profit attributable to shareholders of 22.53 million yuan, up 184.26% year-on-year [1][2] Group 1: Collective Protective Equipment - Revenue from collective protective equipment reached 161 million yuan, growing by 68.31%, with a gross margin of 4.45%, compared to -17.85% the previous year [1][5] - The significant increase in revenue and the turnaround in gross margin are attributed to the first batch of orders for the 239 product, which generated 123.46 million yuan in sales, accounting for 188.67% of the revenue growth in this segment [5][6] - As of the end of 2024, the contract liabilities for collective protective equipment stood at 857,300 yuan, indicating a sustainable revenue outlook based on new orders [6] Group 2: Individual Protective Equipment - Revenue from individual protective equipment fell to 28.44 million yuan, a decline of 59.24%, primarily due to decreased demand [1][8] - The company has no outstanding orders for individual protective equipment as of the end of 2024, but new orders amounting to 97.27 million yuan were received in early 2025, which are expected to support revenue in the next 1-2 years [10][11] Group 3: Pharmaceutical Butyl Rubber Stoppers - The revenue for pharmaceutical butyl rubber stoppers was 334.87 million yuan, a slight increase of 0.78% year-on-year, with a gross margin of 23.07%, down 2.56 percentage points from the previous year [12][13] - The decline in gross margin is attributed to increased competition, a slower adjustment of high-margin product structures, and rising raw material costs [15][24] - The company has implemented measures to optimize production capacity and control costs, resulting in a gross margin of 27.87% for the first quarter of 2025, indicating some recovery [16][24] Group 4: Customer and Supplier Dynamics - The top five customers accounted for 32.16% of total sales, with significant changes due to increased demand for military trade products [25][28] - The top five suppliers represented 51.65% of total purchases, with new suppliers added to meet specific product needs, reflecting a stable supply chain [30]